얼굴용 주사제 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Facial Injectable Market Growth & Trends:

The global facial injectable market size is expected to reach USD 24.9 billion by 2030, registering a CAGR of 12.3% from 2025 to 2030, according to a new report by Grand View Research, Inc., The facial injectables are crucial in anti-aging treatments and are particularly used to stop damage such as hyperpigmentation and early aging. The most popular treatments across all socioeconomic groups are Botox and fillers, which have gained immense popularity.

Growing focus on physical appearance, especially in developing countries is one of the key factors expected to drive the market. In addition, a shift in consumer preference towards minimally invasive procedures is also expected to support market growth. According to the American Society of Plastic Surgeons (ASPS), in 2020, botulinum toxin A and soft tissue fillers were among the top 5 minimally invasive procedures carried out in the U.S. Thus, facial injectable holds high growth prospects in the years to come.

The onset of the pandemic led to nonurgent and cosmetic surgeries being put on hold in the first and second quarters of 2020. Since there were stringent restrictions imposed by the authority bodies as a precaution, the coronavirus outbreak has had an impact on every industry, including the cosmetics industry. Aesthetics-related product supply chains were also impacted. The demand-supply chain across the whole medical device sector has been severely disrupted by the pandemic.

Facial Injectable Market Report Highlights:

• Based on product, the botulinum toxin type A segment is projected to dominate the market throughout the forecast period. It is one of the most popularly used minimally invasive procedures
• Based on application, the facial line correction segment dominated the market and accounted for the largest revenue share of 33.2% in 2024. This growth is owing to the increasing use of facial injectables for aesthetic procedures such as facial lines, wrinkles on the face, and lip lines
• Based on end-use, the medSpa segment dominated the market and held the largest revenue share of 47.0% in 2024. All noninvasive treatments are performed in these facilities, which include facial injections, non-invasive body contouring, skin rejuvenation, and laser treatments by experienced professionals
• North America dominated the market with a revenue share of 38.9% in 2024 owing to the easy availability of the products and the presence of a large number of skilled surgeons
• The Asia Pacific region is expected to serve as a key revenue-generating center. The region is backed by countries such as India, where a growing focus on physical appearance is expected to create a lucrative opportunity for the market

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Application outlook
  • 2.2.3. End Use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Facial Injectable Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing beauty consciousness among consumers
    • 3.2.1.2. Shift in consumer preference towards minimally invasive procedures
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of treatment
• 3.3. Facial Injectable Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Facial Injectable Market: Product Estimates & Trend Analysis

• 4.1. Global Facial Injectable Market: Product Dashboard
• 4.2. Global Facial Injectable Market: Product Movement Analysis
• 4.3. Global Facial Injectable Market by Product, Revenue
• 4.4. Collagen & PMMA Microspheres
  • 4.4.1. Collagen & PMMA microspheres market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Botulinum Toxin Type A
  • 4.5.1. Botulinum toxin Type A market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. HA
  • 4.6.1. HA market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. CaHA
  • 4.7.1. CaHa market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. PLLA
  • 4.8.1. PLLA market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Others
  • 4.9.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Facial Injectable Market: Application Estimates & Trend Analysis

• 5.1. Global Facial Injectable Market: Application Dashboard
• 5.2. Global Facial Injectable Market: Application Movement Analysis
• 5.3. Global Facial Injectable Market Estimates and Forecasts, By Application, Revenue (USD Million)
• 5.4. Facial Line Correction
  • 5.4.1. Facial line correction market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Lip Augmentation
  • 5.5.1. Lip augmentation market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Face Lift
  • 5.6.1. Face lift market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Acne Scar Treatment
  • 5.7.1. Acne scar treatment market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Lipoatrophy Treatment
  • 5.8.1. Lipoatrophy treatment market estimates and forecasts 2018 to 2030 (USD Million)
• 5.9. Others
  • 5.9.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Facial Injectable Market: End Use Estimates & Trend Analysis

• 6.1. Global Facial Injectable Market: End use Dashboard
• 6.2. Global Facial Injectable Market: End use Movement Analysis
• 6.3. Global Facial Injectable Market Estimates and Forecasts, by End use, Revenue (USD Million)
• 6.4. MedSpa
  • 6.4.1. MedSpa market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Dermatology Clinics
  • 6.5.1. Dermatology Clinics market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Hospitals
  • 6.6.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Facial Injectable Market: Regional Estimates & Trend Analysis by Product, Application, and End use

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Mexico
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
  • 8.1.1. Key company market share analysis, 2024
  • 8.1.2. Ispen
    • 8.1.2.1. Company overview
    • 8.1.2.2. Financial performance
    • 8.1.2.3. Product benchmarking
    • 8.1.2.4. Strategic initiatives
  • 8.1.3. Abbvie
    • 8.1.3.1. Company overview
    • 8.1.3.2. Financial performance
    • 8.1.3.3. Product benchmarking
    • 8.1.3.4. Strategic initiatives
  • 8.1.4. Medytox Inc.
    • 8.1.4.1. Company overview
    • 8.1.4.2. Financial performance
    • 8.1.4.3. Product benchmarking
    • 8.1.4.4. Strategic initiatives
  • 8.1.5. Merz GmbH and Co. KGaA
    • 8.1.5.1. Company overview
    • 8.1.5.2. Financial performance
    • 8.1.5.3. Product benchmarking
    • 8.1.5.4. Strategic initiatives
  • 8.1.6. Revance Therapeutics, Inc.
    • 8.1.6.1. Company overview
    • 8.1.6.2. Financial performance
    • 8.1.6.3. Product benchmarking
    • 8.1.6.4. Strategic initiatives
  • 8.1.7. Galderma
    • 8.1.7.1. Company overview
    • 8.1.7.2. Financial performance
    • 8.1.7.3. Product benchmarking
    • 8.1.7.4. Strategic initiatives
  • 8.1.8. Sinclair Pharma
    • 8.1.8.1. Company overview
    • 8.1.8.2. Financial performance
    • 8.1.8.3. Product benchmarking
    • 8.1.8.4. Strategic initiatives